SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+32.69%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$324M
(+21%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-23.19%
Top 10 Holdings %
Top 10 Hldgs %
40.14%
Holding
88
New
16
Increased
27
Reduced
15
Closed
20
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.2M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$9.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$85.4M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$20.7M |
| 3 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$9.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.76M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Intellia Therapeutics
NTLA
$1.22B
| $1.67M | 0.5% | 54,822 +1,804 | +3% | +$55K |
|
52
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.49M | 0.44% | 248,728 -542,943 | -69% | -$3.25M |
|
53
KalVista Pharmaceuticals
KALV
$678M
| $1.37M | 0.41% | 111,734 -117,200 | -51% | -$1.44M |
|
|
MTEM
54
DELISTED
Molecular Templates, Inc.
MTEM
| $1.32M | 0.39% | 354,608 | – | – |
|
55
Trevi Therapeutics
TRVI
$883M
| $1.16M | 0.34% | 863,883 -63,532 | -7% | -$85.1K |
|
56
Schrodinger
SDGR
$1.44B
| $1.11M | 0.33% | 31,117 +806 | +3% | +$28.9K |
|
57
Viridian Therapeutics
VRDN
$1.5B
| $1.1M | 0.33% | 50,438 +3,000 | +6% | +$65.3K |
|
58
Immunovant
IMVT
$2.56B
| $843K | 0.25% | +20,000 | New | +$843K |
|
59
Apellis Pharmaceuticals
APLS
$3.48B
| $599K | 0.18% | +10,000 | New | +$599K |
|
60
Karyopharm Therapeutics
KPTI
$61.7M
| $486K | 0.14% | 561,955 | – | – |
|
61
Aligos Therapeutics
ALGS
$73.3M
| $444K | 0.13% | 668,512 +36,625 | +6% | +$24.3K |
|
62
Relmada Therapeutics
RLMD
$37.2M
| $414K | 0.12% | 100,000 | – | – |
|
63
Rezolute
RZLT
$619M
| $156K | 0.05% | 157,085 -276,155 | -64% | -$274K |
|
|
64
Rocket Pharmaceuticals, Inc. Warrant
RCKTW
$4.26M
| $51.4K | 0.02% | 104,828 | – | – |
|
65
Aclaris Therapeutics
ACRS
$209M
| – | – | 0 | – | – |
|
66
Alkermes
ALKS
$4.78B
| – | – | -41,455 | Closed | -$1.16M |
|
|
JBIO
67
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| – | – | -100,000 | Closed | -$1.36M |
|
68
BioMarin Pharmaceuticals
BMRN
$11.2B
| – | – | -10,000 | Closed | -$885K |
|
69
Clene
CLNN
$53.1M
| – | – | -500,000 | Closed | -$248K |
|
70
Crinetics Pharmaceuticals
CRNX
$2.92B
| – | – | -220,000 | Closed | -$6.54M |
|
71
Gilead Sciences
GILD
$140B
| – | – | -62,789 | Closed | -$4.71M |
|
72
Humana
HUM
$36.5B
| – | – | -10,000 | Closed | -$4.87M |
|
73
Krystal Biotech
KRYS
$4.27B
| – | – | -71,531 | Closed | -$8.3M |
|
74
Novo Nordisk
NVO
$251B
| – | – | -60,000 | Closed | -$5.46M |
|
75
Prothena Corp
PRTA
$441M
| – | – | -26,629 | Closed | -$1.28M |
|